About Zentia

# A decade of WEE1 biology.
One clear mission.

Zentia was founded by scientists who believed the decades of research into cell-cycle control could become a new, more convenient class of cancer therapy — if the right team took it from lab bench to patient.

Meet our leadership → See our approach
Founded 2015 Built on deep biology From first compound to Phase 3 — one team, one focus.

Milestones

## The journey so far

1. 2015

   ### A company is born

   Zentia launches in San Diego, spun from a conviction that WEE1 kinase — a master regulator of the cell cycle — could finally become a druggable target.

2. 2018

   ### First-in-human study

   Our lead molecule enters the clinic, establishing a differentiated oral profile and the first biomarker-defined clinical strategy.

3. 2021

   ### Biomarker breakthrough

   Cyclin E1 amplification emerges as a defining response signature, sharpening our patient selection and trial design.

4. 2023

   ### Registration-intent build

   Late-stage development programs begin, pairing our lead asset with a companion diagnostic across global sites.

5. 2026

   ### Phase 3 ASPENOVA trial

   First patient dosed in our registration-intent Phase 3 trial — a milestone on the path to bringing patients more choice.

What we believe

## Values that guide every decision

01

### Patients first

Every design choice — from once-daily oral dosing to at-home convenience — starts with the person living with cancer.

02

### Science with rigor

We hold ourselves to the highest standard of evidence, letting mechanism and data — not enthusiasm — drive decisions.

03

### Integrity

Transparent, disciplined and honest in everything from clinical reporting to how we treat one another.

04

### Bold collaboration

We partner across academia, patient communities and industry to move faster than any of us could alone.

Today Where we are A focused, late-stage company advancing one of the most studied targets in oncology.

Our progress

## From one hypothesis to a global program

Today Zentia is a team of more than 200 scientists, physicians and operators working across three continents — all focused on one goal: giving patients a targeted, oral option where few non-chemotherapy choices exist.

We are proud of the discipline that got us here: rigorous translational science, a companion diagnostic designed alongside the drug, and trials designed to answer questions patients actually need answered.

- 200+ employees across US and EU
- 40+ active clinical trial sites
- Led by a team with 30+ years of oncology development experience

Join the team → Explore our approach